HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Commercial low-citrate anticoagulation haemofiltration in high risk patients with frequent filter clotting.

Abstract
This study assessed the safety and efficacy of a commercial low-citrate concentration-based pre-filter replacement fluid during continuous veno-venous haemofiltration (CVVH) in patients with frequent filter clotting and high risk of bleeding. We used a commercial low-citrate fluid as pre-dilution replacement fluid during CVVH (citrate: 11 mmol/l (33 meq/l), sodium: 140 mmol/l, chloride: 108 mmol/l and potassium: 1 mmol/l). A calcium and magnesium infusion was delivered separately by central line for the maintenance of serum ionized calcium (Cai) and total magnesium (Mg). In this prospective observational study, 30 patients, 124 filters and 1,515 treatment-hours were observed. Median filter life of citrate CVVH was 9.5 hours. Filter life in the 48 hours prior to citrate CVVH was also observed. In the patients on prior non-anticoagulant CVVH (n=14) filter life increased significantly with citrate (9.5 hours vs 5 hours; P<0.0001). In patients on prior heparin CVVH (n = 15), filter life was similar with citrate (10 hours vs 8 hours; P = 0.68). However, in patients with prior early/frequent filter clotting despite heparin (n = 11) filter life increased significantly (10 hours vs 7 hours; P=0.038). Of 411 serum Cai measurements, none showed a Cai < 0.85 mmol/l and, of 84 observations, none showed a serum Mg<0. 6 mmol/l. One patient with sepsis and shock needed to cease citrate CVVH because of progressive ionized hypocalcaemia and increasing anion gap. No other adverse effects were observed. In selected patients, CVVH with a commercial low-citrate concentration solution as pre-filter replacement fluid and a simultaneous calcium and magnesium infusion protocol appears generally safe. Filter life was acceptable and superior to that achieved with previous treatment.
AuthorsT Naka, M Egi, R Bellomo, L Cole, C French, J Botha, L Wan, N Fealy, I Baldwin
JournalAnaesthesia and intensive care (Anaesth Intensive Care) Vol. 33 Issue 5 Pg. 601-8 (Oct 2005) ISSN: 0310-057X [Print] United States
PMID16235478 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Anticoagulants
  • Citrates
  • Magnesium
  • Calcium
Topics
  • Acute Kidney Injury (therapy)
  • Aged
  • Anticoagulants (therapeutic use)
  • Calcium (blood)
  • Citrates (therapeutic use)
  • Female
  • Hemofiltration (methods)
  • Hospital Mortality
  • Humans
  • Intensive Care Units
  • Magnesium (blood)
  • Male
  • Prospective Studies
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: